The therapy is nearing the end of clinical development, with primary endpoint outcomes anticipated in the first quarter of 2026. Credit: Wasan Tita/Shutterstock.com.

Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), in Canada and the US.

Formycon will complete the development of FYB206, prepare and file the regulatory dossier, and supply the biosimilar product. Zydus will manage its commercialisation.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

FYB206 is nearing the end of clinical development, with primary endpoint outcomes anticipated in the first quarter of 2026.

Upon completion of the data package, Formycon will prepare the dossier for submission of the biologics licence application (BLA) to the US Food and Drug Administration (FDA).

Formycon will receive milestone and upfront payments in the range of €10m to €20m in 2025

Additional payments tied to development and regulatory milestones are expected to be part of this total.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

On market launch of the product, Formycon will receive a mid–double-digit-share of gross profits in the region.

Pembrolizumab is a humanised monoclonal antibody used for treating various tumours.

Zydus Lifesciences managing director Dr Sharvil Patel stated: “We are happy to collaborate with Formycon to develop and commercialise a biosimilar of Keytruda across US and Canada. This venture marks Zydus’ entry into the North American biosimilar market, debuting with an immunotherapy product.

“This collaboration also complements Zydus’ recent proposed acquisition of Agenus’ California, USA-based manufacturing facilities, which we plan to integrate and leverage for manufacturing in the future.

“By combining our expertise and resources, we aim to drive significant organisational growth and deliver maximum value to patients through expanded access to affordable oncology care.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact